Study Title

novartis

NeoPSMA: A Phase I/II, Open-label, Multi-center Study of Neoadjuvant Treatment With [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Adults With Prostate-specific Membrane Antigen (PSMA) Positive High-risk Localized Prostate Cancer (HRLPC) Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection

Study Details

Description:

The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate and lymph nodes present in the pelvis area. Lymph nodes are small structures near the prostate that help fight infections. These lymph nodes are removed during surgery because they are a site the disease can spread to.

Sponsor:

Novartis

Contacts:

Novartis Pharmaceuticals

novartis.email@novartis.com

1-888-669-6682

Drug Details

[177Lu]Lu-PSMA-R2 (AAA602)
Isotope(s):
    LUTETIUM-177
    Radioisotope: Lu-177
    Theranostic Role: Therapeutic Agent & SPECT Imaging
    T1/2 (Half-Life): 6.7 Days
    Decay Mode: BETA, GAMMA
    Energy: Eβeta max 497 keV, Gamma 113-208 keV
    Range: In Tissue: 0.25-2mm
    Decay Daughters: Hf177
    Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
  • LUTETIUM-177
Target(s):
  • PSMA
[225Ac]Ac-PSMA-R2 (AAA802)
Isotope(s):
    ACTINIUM-225
    Radioisotope: Ac-225
    Theranostic Role: Therapeutic Agent & SPECT Imaging
    T1/2 (Half-Life): 9.9 Days
    Decay Mode: ALPHA, GAMMA
    Energy: 5.8-8.4 MeV
    Range: 47-85 micrometers
    Decay Daughters: Ra225, Fr221, At217, Bi213, 209, Po213, 209, TL209, 205
    Status: Clinical Trials Only
  • ACTINIUM-225
Target(s):

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Not yet provided. Contact Novartis Pharmaceuticals for more information.

1-888-669-6682

novartis.email@novartis.com

XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468